Short News

Print

short news

Certificate in Medical Editing
First contact session of Second
Batch to start from October 7th

LAHORE: The first contact session for the Second Batch of Certificate in Medical Editing by University of Health Sciences will start from October 7th to October 10th. Certificates to those who have qualified in the first batch will also be presented to them on the first day October 7th in a special ceremony which is going to be organized during this course.

Special prizes of Rs. twenty five thousand each have also been arranged for the position holders in the first batch i.e. Dr.Saima Chaudhry, Prof. Col.Alamgir Khan, Dr.Shamaila Mohsin, Prof. S. H. Waqar while Dr. Maqbool H.Jafary Memorial Scholarship will also be presented to Noor-i-Kiran Haris who has been selected as the recipient for the Year 2020, during the ceremony. All the selected candidates will also receive the soft copy of Resource Book in the next few days.


Antibiotics linked to higher 
HD with Type-1 Diabetes

Results from a study published in the Journal of Internal Medicine suggest that bacterial infections may elevate the risk of coronary heart disease in individuals with type 1 diabetes. Among 3,781 individuals with type 1 diabetes, 370 developed coronary heart disease over an average follow-up of 13.7 years. Antibiotic purchases, reflecting bacterial infections in outpatient care, were significant risk factors for coronary heart disease, with a 21% increased risk for each annual antibiotic purchase.

A high blood level of bacterial lipopolysaccharides (large molecules derived from the outer layer of gram-negative bacteria) was also a risk factor for coronary heart disease. In broader terms, the present study demonstrates how infections associate with the development of late diabetic complications and perhaps even more importantly, how infections associate with the development of coronary heart disease, as the latter relationship has been disputed during recent years said lead author Johan Rasmus Simonsen, MD, of the Folkhlsan Research Center, in Finland. Interestingly, in our study this association to incident coronary heart disease was seen specifically with antibiotic purchases, making the potential pathophysiologic mechanisms behind this finding intriguing and warranting further studies. Ref: https://onlinelibrary.wiley.com/doi/10.1111/joim.13138


New Trial Results Question 
Standard Treatment Plan
for Rheumatoid Arthritis

In a clinical trial of patients with rheumatoid arthritis, treatment with a drug called upadacitinib provided greater benefits than methotrexate, the most commonly used initial therapy for rheumatoid arthritis.

Upadacitinib inhibits certain proteins called Janus kinase enzymes that are involved in inflammation. It’s approved for treating patients with rheumatoid arthritis, but only after they have tried methotrexate.

In the study published in Arthritis & Rheumatology, 947 patients who had not previously taken methotrexate were randomized to receive once-daily upadacitinib (15 mg or 30 mg) or weekly methotrexate for 24 weeks. Both doses of upadacitinib lessened clinical signs of arthritis and improved patient-reported symptoms to a greater extent than methotrexate. Importantly, both doses prevented further joint damage in 88% to 89% of patients, compared with 78% of patients taking methotrexate.Treatment with the 30 mg dose provided minimal additional efficacy compared with the 15 mg dose, but it was linked with a higher rate of side effects.

This trial convincingly demonstrates the efficacy of the JAK inhibitor upadacitinib as monotherapy in early rheumatoid arthritis. It works faster and better than methotrexate alone, said lead author Ronald van Vollenhoven, MD, of the Amsterdam University Medical Centers, in The Netherlands.The latter drug can be combined with corticosteroids to obtain a more rapid effect, and future studies will perhaps use that comparison.

Ref: https://onlinelibrary.wiley.com/doi/10.1002/art.41384

© Professional Medical Publications. All rights reserved.